Eli Lilly plans to sustain its aggressive dealmaking pace in 2026, corporate development chief Jacob Van Naarden tells Axios Pro.
The big picture: Fueled by obesity drug success, Lilly is directing more cash to early-stage biotech deals, including companies in Phase 1 and Phase 2 trials.
